GlassScriptPhysician profile
Alexis Lukach
NPI 1497249387
$4,753.24
in general payments reported to CMS, 2019-2025
24 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $471 · 2023: $1,469 · 2024: $1,420 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,002 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.74 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $944.33 | 2022-2025 | Tremfya |
| Abbvie INC. | $512.08 | 2022-2025 | |
| Lilly USA, LLC | $439.49 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $342.33 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $296.93 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $295.96 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $273.00 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $269.66 | 2022-2025 | Ilumya |
| Genzyme Corporation | $226.03 | 2023-2025 | |
| Amgen INC. | $223.14 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $190.10 | 2024-2025 | Adbry, Anzupgo |
| Pfizer INC. | $157.85 | 2023-2025 | |
| Galderma Laboratories, L.P. | $121.70 | 2021-2025 | Aklief, Nemluvio |
| Arcutis Biotherapeutics, INC. | $115.33 | 2023-2025 | Zoryve |
| Merz North America, INC. | $106.41 | 2023 | Xeomin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.31 | 2021-2025 | Cabtreo |
| Botanix Sb INC | $52.09 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.59 | 2024 | Spevigo |
| Blueprint Medicines Corporation | $24.11 | 2025 | Ayvakit |
| Revance Therapeutics, INC. | $16.67 | 2025 | Daxxify |
| Lnhc, INC | $14.83 | 2025 | Zelsuvmi |
| Dermavant Sciences, INC. | $12.99 | 2023 | Vtama |
| Mayne Pharma Commercial LLC | $11.44 | 2023 | |
| Organon LLC | $6.87 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Lukach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.